NCT05569148View on ClinicalTrials.gov

A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions

Neovascular Age-related Macular DegenerationDiabetic Macular Edema

Interventions

COMBINATION_PRODUCT

Faricimab PFS Configuration

Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.

Trial Locations (3)

85020

Associated Retina Consultants, Phoenix

85053

Retinal Consultants of Arizona, Phoenix

85206

Barnet Dulaney Perkins Eye Center, Mesa

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY